Indication
Squamous Cell Carcinoma of the Head and Neck
71 clinical trials
88 products
14 drugs
Clinical trial
A Phase 1 Study of SGN-PDL1V in Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-07-31
Product
SGN-PDL1VProduct
pembrolizumabClinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)Status: Active (not recruiting), Estimated PCD: 2024-08-11
Product
AtezolizumabProduct
TiragolumabProduct
PaclitaxelProduct
CarboplatinProduct
177Lu-3BP-227Clinical trial
An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1Status: Terminated, Estimated PCD: 2020-04-03
Clinical trial
A Phase 1 Study of SGN-EGFRd2 in Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2027-07-31
Product
SGN-EGFRd2Product
XmAb®23104Clinical trial
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
YervoyProduct
XevinapantClinical trial
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
PlaceboProduct
CisplatinProduct
MonalizumabProduct
CetuximabClinical trial
A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Participants With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint InhibitorStatus: Active (not recruiting), Estimated PCD: 2022-05-11
Product
JANX008Clinical trial
An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2026-01-01
Product
CMAB819Product
NivolumabClinical trial
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckStatus: Terminated, Estimated PCD: 2023-10-16
Clinical trial
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid TumorsStatus: Recruiting, Estimated PCD: 2029-08-09
Product
LN-145-S1Product
LifileucelProduct
LN-145Product
PembrolizumabProduct
IpilimumabProduct
PF-06940434Product
PF-06801591Clinical trial
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORSStatus: Active (not recruiting), Estimated PCD: 2024-08-30
Product
PF-07257876Clinical trial
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORSStatus: Completed, Estimated PCD: 2023-10-24
Clinical trial
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced MalignanciesStatus: Terminated, Estimated PCD: 2023-03-06
Product
XmAb20717Clinical trial
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORSStatus: Recruiting, Estimated PCD: 2027-01-31
Product
PF-07820435Product
SasanlimabClinical trial
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid MalignanciesStatus: Recruiting, Estimated PCD: 2025-10-31
Product
Brentuximab vedotinClinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Product
AcasunlimabClinical trial
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-06-01
Product
SEA-CD40Clinical trial
A Multicentre, Open-label, Dose-escalating, Phase Ib, Study of Intravenous Dosing of NG-641, as Monotherapy or in Combination With Pembrolizumab in Patients With Surgically Resectable Squamous Cell Carcinoma of the Head and NeckStatus: Recruiting, Estimated PCD: 2024-09-01
Product
NG-641Product
TQB2618Product
Penpulimab injectionClinical trial
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)Status: Completed, Estimated PCD: 2023-02-16
Product
XmAb®22841Clinical trial
A Randomized, Open, Multicenter Phase 1/Phase 2 Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2024-08-01
Product
SNS-301Product
Modi-1/Modi-1vClinical trial
A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients With Breast, Head and Neck, Ovarian, or Renal CancerStatus: Recruiting, Estimated PCD: 2026-04-04
Product
GemcitabineProduct
Nab-paclitaxelClinical trial
An Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and NeckStatus: Terminated, Estimated PCD: 2021-06-28
Clinical trial
A Pilot Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)Status: Completed, Estimated PCD: 2022-12-01
Product
[18F]F-AraG PET ScanProduct
OzuriftamabClinical trial
A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in PD-1/L1 Failure Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckStatus: Recruiting, Estimated PCD: 2024-12-01
Product
PD-1 inhibitorProduct
AMG 228Clinical trial
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2016-12-12
Product
MRG003Clinical trial
A Randomized, Open-Label, Multicenter, Phase III Study to Evaluate MRG003 vs Cetuximab/Methotrexate as Second/Third Line of Treatment in Patient With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN)Status: Not yet recruiting, Estimated PCD: 2025-08-01
Product
MethotrexateClinical trial
An Open-label Phase 2 Study of Dalantercept in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckStatus: Completed, Estimated PCD: 2015-06-01
Clinical trial
An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)Status: Completed, Estimated PCD: 2015-11-06
Product
DalanterceptProduct
DocetaxelProduct
PF-07209960Clinical trial
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145/LN-145-S1) for the Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckStatus: Completed, Estimated PCD: 2022-08-08
Product
AAV2hAQP1Clinical trial
Open-Label, Dose-Escalation Study Evaluating the Safety of a Single Administration of an Adeno-Associated Virus Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in Individuals With Irradiation-Induced Parotid Salivary HypofunctionStatus: Active (not recruiting), Estimated PCD: 2026-07-01
Clinical trial
A French Prospective, Non-interventional Research ( NIR) of Nivolumab in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After a Platinum-based TherapyStatus: Active (not recruiting), Estimated PCD: 2024-09-08
Clinical trial
Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or LymphomasStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Product
SL-279252Clinical trial
A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced MalignanciesStatus: Completed, Estimated PCD: 2021-08-18
Product
EtrumadenantProduct
ZimberelimabClinical trial
Depleting Exosomes to Improve Response to Immune Therapy in Head and Neck Squamous Cell Cancer: An Early Feasibility Phase I Clinical TrialStatus: Terminated, Estimated PCD: 2022-11-14
Clinical trial
A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 With or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination With Pembrolizumab in Subjects With Advanced Solid MalignanciesStatus: Recruiting, Estimated PCD: 2024-06-30
Product
ST-067Product
ObinutuzumabProduct
CPI-006Clinical trial
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERSStatus: Completed, Estimated PCD: 2022-12-28
Product
CPI-006 + PembrolizumabClinical trial
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORSStatus: Terminated, Estimated PCD: 2023-05-03
Clinical trial
Phase II Trial of Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard TherapiesStatus: Active (not recruiting), Estimated PCD: 2022-06-01
Product
Mitomycin-CProduct
PegfilgrastimClinical trial
Priming Immunotherapy in Advanced Disease With RadiationStatus: Active (not recruiting), Estimated PCD: 2024-02-16
Product
Immune checkpoint inhibitorClinical trial
Multicenter Prospective Single Arm Phase II Study Evaluating Efficacy & Safety of Durvalumab With Carboplatin/Paclitaxel as First Line Treatment in Patients With Recurrent/Metastatic SCCHN Not Eligible to Standard ChemotherapyStatus: Completed, Estimated PCD: 2020-05-16
Clinical trial
A Phase 1 Trial of CTLA-4 Inhibition, With or Without Cetuximab, and in Combination With Memory-like Natural Killer (NK) Cell Immune Cell Therapy in Advanced Head & Neck CancerStatus: Recruiting, Estimated PCD: 2024-06-01
Product
Interleukin-15 SuperagonistProduct
CIML NK cell InfusionClinical trial
Integrated Pilot Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerStatus: Recruiting, Estimated PCD: 2024-07-26
Product
VX15/2503Clinical trial
Phase I/Ib Trial of Radiotherapy in Combination With Durvalumab (MEDI4736) Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma of the Head and Neck (HNSCC)Status: Active (not recruiting), Estimated PCD: 2021-11-23
Drug
AN0025Clinical trial
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) CancerStatus: Recruiting, Estimated PCD: 2028-01-10
Drug
DocetaxelDrug
CisplatinDrug
PRGN-2009Clinical trial
Pembrolizumab and Radiotherapy for OLigometastatic Squamous Cell Carcinoma of the Head and Neck: a Randomized Phase III StudyStatus: Not yet recruiting, Estimated PCD: 2027-07-15
Clinical trial
Ph II Trial to Assess Feasibility+Efficacy of Treatment w Durva+Treme+Radiation and Treatment w Durva+Radiation as First-line Therapy for Patients w Non-resectable Locally Advanced HPV-HNSCC- a Comparision With a Historical Control GroupStatus: Completed, Estimated PCD: 2023-08-17
Product
TremelimumabClinical trial
A Phase II Trial of Carboplatin, Paclitaxel, and Nivolumab Induction Therapy Followed by Response-stratified Locoregional Therapy for Patients With Locally Advanced, HPV-negative Head and Neck Cancer. The DEPEND Trial.Status: Recruiting, Estimated PCD: 2024-07-01
Drug
TiragolumabDrug
T-VECProduct
HydroxyureaDrug
fluorouracilProduct
FilgrastimClinical trial
A Randomized, Double-blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence - the PATHWay Study.Status: Active (not recruiting), Estimated PCD: 2025-06-20
Drug
VarlilumabClinical trial
Intratumoral Ipilimumab in Head and Neck CancerStatus: Active (not recruiting), Estimated PCD: 2019-09-21
Clinical trial
A Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell CarcinomaStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Drug
N-803Drug
pembrolizumabProduct
PD-L1 t-haNK cellsClinical trial
Guided by Light: Optimizing Surgical Excision of Oral Cancer Using Real-time Fluorescence ImagingStatus: Recruiting, Estimated PCD: 2024-09-01
Product
cRGD-ZW800-1.Clinical trial
Multimodality Risk Adapted Therapy Including Carboplatin/Paclitaxel/Lapatinib as Induction for Squamous Cell Carcinoma of the Head and Neck Amenable to Transoral Surgical ApproachesStatus: Active (not recruiting), Estimated PCD: 2016-11-01
Product
LapatinibClinical trial
Preclinical and Clinical Study of Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and NeckStatus: Active (not recruiting), Estimated PCD: 2019-04-11
Product
Valproic AcidClinical trial
A Double-blind, Randomized, Phase III Study of Radiotherapy Combined With cetuXimab + Xevinapant Compared to Radiotherapy Combined With Cetuximab (Standard of Care) + Placebo in Patients With LA SCCHN, Unfit for High-dose CisplatinStatus: Recruiting, Estimated PCD: 2024-07-01
Drug
cetuximabClinical trial
Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Treatment of Advanced Squamous Cell Cancers of the Head and NeckStatus: Recruiting, Estimated PCD: 2024-12-01
Drug
afatinibClinical trial
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2022-04-05
Clinical trial
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck CancerStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2023-07-05
Product
IRX-2Clinical trial
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.Status: Completed, Estimated PCD: 2021-01-12
Product
GR-MD-02Clinical trial
Pilot Study Evaluating Panitumumab-IRDye800 and 89Zr-Panitumumab for Dual-Modality Imaging for Nodal Staging in Head and Neck CancerStatus: Completed, Estimated PCD: 2020-12-11
Product
Panitumumab-IRDye800Product
89-Zirconium PanitumumabClinical trial
A Phase II Study Evaluating the Interest to Combine UCPVax a CD4 TH1-inducer Cancer Vaccine and Atezolizumab for the Treatment of Human PapillomaVirus Positive CancersStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Product
Blood sample collectionDrug
AtezolizumabProduct
UCPVaxClinical trial
Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck CancersStatus: Not yet recruiting, Estimated PCD: 2025-04-01
Product
GCP intratumoral catheterClinical trial
A Multi-Institutional, Open-Label, Randomized, Phase II Trial Of Ibrutinib In Combination With EGFR Inhibition Or PD-1 Inhibition In Patients With Recurrent/Metastatic Head And Neck Squamous Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-01-11
Product
IbrutinibClinical trial
The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical ActivityStatus: Completed, Estimated PCD: 2021-02-21
Product
IRX 2Drug
mFOLFOX6Clinical trial
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2022-01-19
Product
ARG1-18,19,20Clinical trial
HMBD-001 (an Anti-HER3 Monoclonal Antibody) Given Intravenously as a Single Agent and in Combination in Patients With Advanced HER3 Positive Solid TumoursStatus: Recruiting, Estimated PCD: 2026-09-01
Product
HMBD-001Clinical trial
A Phase II Randomized Study to Determine the Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and NeckStatus: Completed, Estimated PCD: 2022-10-01
Clinical trial
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): "The APA Trial".Status: Active (not recruiting), Estimated PCD: 2019-12-12
Product
nab-PaclitaxelClinical trial
A Phase II Trial of Personalized Immunotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck That Have Progressed on Prior ImmunotherapyStatus: Active (not recruiting), Estimated PCD: 2023-08-12
Product
Nivolumab+RelatlimabProduct
Nivolumab+IpilimumabClinical trial
Phase I Study of Afatinib With Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)Status: Completed, Estimated PCD: 2017-11-20
Product
AfatinibClinical trial
Biomarker Driven Phase 1/1b Trial of ASTX727 and Nivolumab in Patients With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and NeckStatus: Not yet recruiting, Estimated PCD: 2025-02-28
Product
INQOVIProduct
Keytruda